The proportion of patients who developed oral candidiasis IL-17 therapy in our cohort may be partially explained by the relatively small sample size and the high prevalence of metabolic comorbidities, such as diabetes and obesity, which are recognized risk factors for candidiasis. Here, IL17A is linked to obesity disorder.